Preferred Label : guselkumab;
Obsolete resource : false;
MeSH hyponym : CNTO-1959;
UNII : 089658A12D;
Origin ID : C000588857;
UMLS CUI : C3852217;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH indexing information
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3539084/fr/tremfya-guselkumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
injections, subcutaneous
guselkumab
biological therapy
chronic disease
---
https://www.has-sante.fr/jcms/p_3363296/fr/tremfya-guselkumab-psoriasis-en-plaques-de-l-adulte
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
psoriasis
injections, subcutaneous
guselkumab
Interleukin Inhibitors
evaluation of the transparency committee
guselkumab
---
https://www.has-sante.fr/jcms/p_3271021/fr/tremfya-guselkumab-rhumatisme-psoriasique
2021
false
false
false
France
evaluation of the transparency committee
guselkumab
antibodies, monoclonal
antibodies, monoclonal, humanized
treatment outcome
insurance, health, reimbursement
arthritis, psoriatic
adult
drug therapy, combination
methotrexate
guselkumab
injections, subcutaneous
Interleukin-23
---
https://www.has-sante.fr/jcms/p_3162058/fr/tremfya
2020
false
false
false
France
guselkumab
guselkumab
insurance, health, reimbursement
treatment outcome
injections, subcutaneous
psoriasis
adult
chronic disease
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2908438/fr/tremfya
2019
false
true
false
false
France
Injectable Solution Dosage Form
guselkumab
antibodies, monoclonal
Pre-filled Pen Syringe
psoriasis
adult
insurance, health, reimbursement
evaluation of the transparency committee
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
guselkumab
guselkumab
guselkumab
adult
psoriasis
injections, subcutaneous
Interleukin-23
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antibodies, monoclonal
antibodies, monoclonal
interleukin-23 subunit p19
arthritis, psoriatic
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00387
2018
false
false
false
Canada
French
English
drug information
guselkumab
drug evaluation
drug approval
canada
treatment outcome
product surveillance, postmarketing
guselkumab
injections, subcutaneous
interleukin-23 subunit p19
immunomodulators
immunomodulators
psoriasis
adult
guselkumab
antibodies, monoclonal
immunologic factors
immunologic factors
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2877053/fr/tremfya
https://www.has-sante.fr/portail/jcms/c_2877053/fr/tremfya-guselkumab-immunosuppresseur-inhibiteur-de-l-interleukine-23
2018
false
false
false
France
French
treatment outcome
guselkumab
guselkumab
adult
psoriasis
injections, subcutaneous
Interleukin-23
evaluation of the transparency committee
guidelines for drug use
antibodies, monoclonal
---
